Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.60 |
| ▸ | MAP2K2 | P36507 | 17/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313218 | 0.85 | MAP2K1 (0.57) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL21471500 | 0.82 | MAP2K1 (0.41) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL390960 | 0.77 | MAP2K1 (0.63) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL1350931 | 0.77 | ERN1 (0.52) | MAP2K1MAP2K2 | |
| SCHEMBL29425373 | 0.76 | MAP2K1 (0.67) | MAP2K1MAP2K2 | |
| SCHEMBL1562380 | 0.76 | MAP2K1 (0.67) | MAP2K1MAP2K2 | |
| SCHEMBL188505 | 0.75 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29413395 | 0.75 | MAP2K1 (0.80) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL1488448 | 0.75 | MAP2K1 (0.80) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29413559 | 0.75 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | claimed |
| US-20050059710-A1 | Diphenylamino ketone derivatives as MEK inhibitors | PFIZER INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059710-A1 | Diphenylamino ketone derivatives as MEK inhibitors | BRAF, RAF1, MAP3K1 | MAP2K1 31/4885MAP2K2 26/4885PIM1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.